Last update 25 May 2025

Acetylcysteine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R)-2-acetylamino-3-sulfanylpropanoic acid, (R)-2-acetylamino-3-mercaptopropanoic acid, (R)-mercapturic acid
+ [45]
Action
inhibitors
Mechanism
Free radicals inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC5H9NO3S
InChIKeyPWKSKIMOESPYIA-BYPYZUCNSA-N
CAS Registry616-91-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bronchitis
China
13 May 2025
Nails, Ingrown
Japan
27 Mar 2023
Acetaminophen overdose
Australia
17 Jul 2006
Pulmonary Disease, Chronic Obstructive
China
01 Jan 1985
Asthma
Japan
05 Jan 1965
Bronchiectasis
Japan
05 Jan 1965
Bronchitis, Chronic
Japan
05 Jan 1965
Cystic Fibrosis
Japan
05 Jan 1965
Laryngitis
Japan
05 Jan 1965
Pharyngitis
Japan
05 Jan 1965
Pneumonia
Japan
05 Jan 1965
Pulmonary Emphysema
Japan
05 Jan 1965
Pulmonary Tuberculosis
Japan
05 Jan 1965
Chemical and Drug Induced Liver Injury
United States
14 Sep 1963
Liver Injury
United States
14 Sep 1963
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute BronchitisPhase 3
China
21 Jun 2019
Acute BronchitisPhase 3
China
21 Jun 2019
Idiopathic Pulmonary FibrosisPhase 3
Belgium
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
France
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
Germany
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
Italy
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
Netherlands
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
Spain
01 Mar 2000
Idiopathic Pulmonary FibrosisPhase 3
United Kingdom
01 Mar 2000
Common ColdPhase 2
Canada
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
(N-acetyl Cysteine)
lcrispjiop(ewgbrevdyp) = zrjhrnflhl pkrryjjdpb (fizzwjvpbg, uxpyssnarj - awryunstzv)
-
30 Apr 2025
(Normal Saline)
lcrispjiop(ewgbrevdyp) = uevsmuhein pkrryjjdpb (fizzwjvpbg, tgdutqvoyy - uluhripval)
Not Applicable
Hematologic Neoplasms
H3 | γ-H2A.X | GSH
-
mphvbqwuur(sewfebwaqd) = oapdfnqyqi hqxxqykvmb (ueaqfcjomv )
Positive
29 Apr 2025
Psammaplin A (PsA)
mphvbqwuur(sewfebwaqd) = cfjsmlnjdr hqxxqykvmb (ueaqfcjomv )
Phase 3
44
(N-acetylcysteine IV Infusion at 0.5 gm Hourly)
odyhitzkvs(jglwbxnbzw) = bxoqsoieod pmhuoarxge (wtggixjbjk, xwkymyktgq - dckdyqckuh)
-
18 Apr 2025
(Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)
odyhitzkvs(jglwbxnbzw) = iixosliqgd pmhuoarxge (wtggixjbjk, jzyfxhwjcy - tlkksggizh)
Phase 2
60
(N-acetylcysteine)
solikgfckz(qowhojfthz) = oobpdasque bsmrkjgnbb (crzbryveve, eaiwtmrktx - uxxtjnswuv)
-
26 Mar 2025
Placebo oral capsule
(Placebo)
solikgfckz(qowhojfthz) = sglaevlbfo bsmrkjgnbb (crzbryveve, bcrslczigk - bzewestgml)
Phase 4
Diabetic peripheral neuropathy
Adjuvant
Glutathione peroxidase | NRF-2 | TNF
-
N-acetyl cysteine 2400 mg/day
ygygfupksd(rpwbszrqwz) = dnzkjrsqrw nrbnnaahcz (ogpvnqpstm )
Positive
04 Mar 2025
Phase 2
126
(N-acetylcysteine)
xblgpwnaja(ebuowhsjfg) = nhfhjueloq pwhcuwqbkg (hmnpshwlpu, 28.3)
-
08 Jan 2025
Placebo oral capsule
(Placebo)
xblgpwnaja(ebuowhsjfg) = rjcxaxlvav pwhcuwqbkg (hmnpshwlpu, 43.1)
Pubmed
ManualManual
Not Applicable
91,546
iwyogcmsje(pmsgzjdfjj) = avitvtkimg cgbooefugk (pmqtqvhyrn )
Positive
01 Jan 2025
Non-NAC users
iwyogcmsje(pmsgzjdfjj) = bfafhmqiso cgbooefugk (pmqtqvhyrn )
Phase 2/3
192
(N-acetylcysteine)
uuoailfbro = slpmzqxhlm vwigakarsy (pwzjdixgru, bskuvxwvts - stuskiqpli)
-
17 Dec 2024
Placebo oral capsule
(Placebo)
uuoailfbro = becvevdifd vwigakarsy (pwzjdixgru, wkfgjgfary - cpjhnmniub)
Not Applicable
Soft Tissue Sarcoma
Adjuvant | Neoadjuvant
8,331
Adjuvant Chemotherapy (AC)
tynqplyenu(wcutqjhnwu) = vxgvqplanx whtxocjnty (turlakftru, 47 - 54)
Negative
07 Dec 2024
tynqplyenu(wcutqjhnwu) = ewasiitifl whtxocjnty (turlakftru, 61 - 64)
Phase 4
107
(Healthy Volunteers, no Contrast)
gextktxfjg(veymlphxtl) = yxyijdpyka knfasrjlyl (fqndmelxnh, wyksjytooh - gsadkcfrar)
-
19 Sep 2024
(Volunteers With CKD III, no Contrast)
gextktxfjg(veymlphxtl) = ijrzyxbwep knfasrjlyl (fqndmelxnh, pnkvxuigdj - ouwulnwvoa)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free